Posters –
Immunology and Oncology
NAME OF THE PROJECT
NAME OF THE MAIN CONTACT
ORGANISATION NAME
CD47
herve.ansanay@sattnord.fr
SATT Nord
Technology
A novel CD47-derived peptide, called TAX2, is able to inhibit in vitro and ex vivo
angiogenesis features in a TSP-1-dependent manner. Consistently, our data highlighted
that TAX2 promotes TSP-1 binding to CD36-containing complexes, leading to disruption of
VEGFR2 activation and downstream NO signaling. A multimodal imaging approach was
conducted. TAX2 in vivo administrations highly disturb tumor vascularization in both
allograft and human xenograft melanoma models, therefore inducing extensive tumor
necrosis. TAX2 also strongly inhibits growth rate and vascularization of human ovarian
and pancreatic carcinoma xenografts in nude mice. Metastatic dissemination was also
inhibited under TAX2 treatment, while PK/ADME and toxicity studies revealed suitable
stability and absence of adverse effects.
Customers / Target market
According to a new report released by the IMS Institute for Healthcare Informatics, total
global spending on oncology medicines – including therapeutic treatments and
supportive care – reached the $100 billion threshold in 2014. Oncology drug spending has
risen slightly as a percentage of total drug spending over the past five years in all regions,
most notably in the EU5 countries where oncology now represents 14.7 percent of total
drug spending.
Industry and competitors
This important therapeutic domain is attractive and a lot of biopharmas are in
competition… The top 10 pharma companies by oncology sales are Roche, Novartis,
Celgene, Johnson & Johnson, Bristol-Myers Squibb, Lilly, Takeda, AstraZeneca, Merck &
Co. and Amgen. Nevertheless a lot of biotechs are also developing pertinent approaches,
tools, molecules, biologics to tackle the cancer progression.
Financing need / Commercial
opportunity
We are open for discussion on out-licensing opportunities with potential co-development
partner(s)
SATT Nord is currently providing funds for a maturation step.
IP – Patent situation
Patent FR1156237 filled on 2011, July 8th and issued 2013, August 30th
Extension PCT/FR2012/051593, on 2012, July 6th
Countries: Europe (EP12738574.8), Canada (CA2840719), United States (14/131275) and
Japan: 2014-517900
Future steps / Milestones
We are looking for expertise to develop the drug candidate.
Further reading
N/A
Contact person
Herve
Ansanay,
PhD,
herve.ansanay@sattnord.fr
Business
Developer,
SATT
Nord